Julie is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and in the filings of Investigational New Drug (IND) applications, Biologics License Applications (BLA) and Special Protocol Assessments (SPA). Julie recently served as interim CEO at Arch Oncology. Previously, she served as senior vice president, chief medical officer, and head of development at IDEAYA Biosciences, an oncology company. Prior to her role at IDEAYA, she held the positions of vice president and head of U.S. Medical at Bristol-Myers Squibb, where she oversaw medical & health economic and outcomes research activities in support of the oncology, immuno-oncology, specialty and cardiovascular marketed portfolios; executive vice president and chief medical officer at Five Prime Therapeutics; and vice president of clinical development at Clovis Oncology. Julie began her industry career at Genentech, most recently as group medical director, global clinical development. She also serves on the boards of directors of IGM Biosciences, Inc., and SpringWorks Therapeutics, Inc., both publicly traded biotechnology companies, as well as Accent Therapeutics, a privately held biotechnology company. Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003, and was Board-certified in hematology and internal medicine. She received her M.D. from Case Western Reserve University School of Medicine and a B.S. from Duke University.